✦ LIBER ✦

Optimising the therapeutic ratio in head and neck cancer

✍ Scribed by Alexander W Eckert; Johannes Schubert; Helge Taubert

Book ID: 117785333
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 128 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70074-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimising the therapeutic ratio in head

Optimising the therapeutic ratio in head and neck cancer

✍ June Corry; Lester J Peters; Danny Rischin 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 174 KB

Improving the therapeutic ratio in head

Improving the therapeutic ratio in head and neck cancer

✍ Robin Prestwich; Karen Dyker; Mehmet Sen 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 142 KB

Advances in molecular diagnostics and th

Advances in molecular diagnostics and therapeutics in head and neck cancer

✍ Raymond Liu Chai; Jennifer Rubin Grandis 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 380 KB

Operative treatment of head and neck can

Operative treatment of head and neck cancer in the elderly—an optimised approach

✍ D. Komath; B. Visavadia 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Neoadjuvant cisplatin for head and neck

Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio

✍ Loredana G. Marcu; Eva Bezak 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 493 KB

Head and neck cancer: Response to p53-ba

Head and neck cancer: Response to p53-based therapeutics

✍ Jackie Nemunaitis; John Nemunaitis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

## Abstract Limited options are available for patients with advanced stage head and neck cancer. The p53 gene is known as the “guardian of the genome.” Mutations of the p53 gene predispose to carcinogenesis. The p53 mutations are common in head and neck cancer. Replacement of p53 gene function in p